After a prolonged slowdown, private equity distributions are showing some signs of life. Yet is it premature to call the drought over? A massive imbalance between capital in the ground and available demand is forcing a fundamental "shakeout" of PE distributions that is reshaping how GPs generate returns and how LPs manage their portfolios — the subject of a recent AlphaSense webinar with Ted Seides, founder of Capital Allocators. This report leverages key insights from Seides and those available in AlphaSense to explore the trends shaping the PE landscape heading into 2026.
Private Equity Distributions: Assessing the Potential Recovery
About the Authors
Xavier Smith, Director of Research, Energy & Industrials
Xavier serves as the Director of Research, Energy and Industrials at AlphaSense. Before joining AlphaSense, Xavier worked as an equity portfolio manager at various firms including Goldman Sachs, and Gugenheim. Xavier has equity market experience in London as well as New York. Xavier received an MBA from the Wharton School and a BA from Tulane University.
Sean Carmichael
Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.
Explore more
APAC Macro Briefing 2026: Risk Meets Opportunity
In this report, we show how resources and workflows available in the AlphaSense platform can help contextualize the APAC macro environment, exploring the key implications for corporate leaders and investors across sectors.
Top AI Use Cases for Private Equity
In this report, discover how private equity teams are leveraging AI to accelerate conviction with speed. With purpose built, AI-driven solutions like AlphaSense, teams are gaining a competitive advantage with custom workflows and unmatched content sets for the most differentiated deal intelligence.
AI in Drug Development 2026: From Experimentation to Execution
Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.
Transform intelligence
into advantage
Develop bold strategies, seize opportunities, and lead with clarity and confidence.